DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
Obesity Medicines 2026 — Part 1: sector map for investors
A stock-market overview built around the names that matter most in the public conversation today: Novo Nordisk (NVO), Eli Lilly (LLY), Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), Altimmune (ALT), Fractyl Health (GUTS) and Zealand Pharma (ZEAL). This first part is not a medical explainer. It is a market map: who already has real commercial power, who is still trying to earn strategic relevance, and which catalysts actually matter for the shares.
Obesity Medicines 2026 Part 2
Part 2 moves from the sector to the stocks themselves. Each company is examined through the same lens: ticker, core asset, stage, regulatory standing, commercial position, why the market cares, bull case, bear case and the next likely stock-moving issues. The goal is not to crown a winner but to show what each public name really is today.
Three March PDUFAs retail biotech traders are watching most closely
March is packed with biotech catalysts, but for many retail traders the shortlist comes down to three names: Lantheus, Aldeyra and Rocket Pharmaceuticals. They are very different stories — one radiopharma platform name, one dry-eye binary, one rare-disease gene-therapy approval setup — but all three have the ability to move fast around FDA timing, market expectations and headline interpretation.
Atara Biotherapeutics (ATRA): after the new tabelecleucel update, a second attempt at an FDA path
Two months after the FDA’s complete response letter on tabelecleucel for EBV+ PTLD, Atara and partner Pierre Fabre are back in Washington with a Type A meeting request and a thick briefing book. The goal is simple but ambitious: convince the agency that the data set behind EBVALLO, already approved in Europe, can still support a viable U.S. path despite the sudden change of tone on the ALLELE trial.
Altimmune Inc ( $ALT ) Q4 2025 results and plans 2026 global Phase 3 MASH
Altimmune closes 2025 with $274 million in cash and short-term investments and roughly $340 million pro forma after a January 2026 direct offering, while its lead asset pemvidutide moves toward a global Phase 3 trial in MASH and a key Phase 2 readout in alcohol use disorder (RECLAIM) expected in Q3 2026.
CorMedix (CRMD) – From single-asset grind to commercial anti-infective platform
A narrative and technical deep dive on CorMedix after full-year 2025 and Q4 numbers: what DefenCath plus Melinta really changed, how the new P&L looks, and where the risk-reward sits going into 2026–2027.
BioXcel Therapeutics Inc ( $BTAI ) BXCL501 in opioid withdrawal
Positive topline Phase 2 results from a Columbia University-led study suggest that BXCL501 may match or outperform lofexidine in opioid withdrawal, with a cleaner tolerability profile. But BioXcel is still a small-cap with a fragile balance sheet: can this new data point reshape the long-term story for IGALMI/BXCL501 and the broader pipeline?
Verastem Oncology ( $VSTM )
First commercial year for AVMAPKI FAKZYNJA CO-PACK in KRAS-mutant LGSOC delivered $30.9M in net product revenue, Japan’s RAMP 201J bridged exposure and responses in both KRAS-mutant and wild-type disease, and management now promises a self-sustaining LGSOC franchise by 2H 2026 — with RAMP 301 confirmatory data only in mid-2027.
Aquestive Therapeutics ( $AQST ): Anaphylm after the CRL
Aquestive remains pre-commercial on Anaphylm, with a manufacturing-driven revenue base, a sizeable cash cushion and a clearly negative EBITDA profile in 2026 as it funds the resubmission and maintains a pre-launch infrastructure.
BriaCell Therapeutics Corp ( $BCTX ) Phase 3 BRIA-ABC
BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing cell-based therapies for advanced breast cancer and other solid tumors. The core asset, Bria-IMT™ plus a checkpoint inhibitor, is in a pivotal Phase 3 study (BRIA-ABC) in heavily pre-treated metastatic breast cancer (MBC) under FDA Fast Track designation.
Ocugen Inc ( $OCGN ) MAR 04 Bussines Update
Q4 2025 business update in focus: where Ocugen stands after another loss-making year, how the OCU400/410 platform is evolving, and what really matters for the next 18–24 months in gene therapy and anti-aging.
Klotho Neurosciences Inc. ( $KLTO )
EN IT NASDAQ: KLTO Klotho Neurosciences Inc. Gene Therapy for Neurodegeneration + Strategic Minerals Division Market Cap: ~$39.6M | Price: $0.54 | YTD: -86.2% Chart: 1-year daily bars | Current Price: $0.54 | 52-week range: $0.11–$3.91 Data as of March…
Can-Fite Biopharma Ltd ADR ( $CANF )
Deep dive after the March 4, 2026 Phase IIa update of Namodenoson in advanced pancreatic ductal adenocarcinoma (PDAC), with a full look at pipeline, balance sheet, governance, bull & bear case, and retail sentiment.
Tilray Brands Inc ( $TLRY ) From cannabis hype to beer-and-cannabis conglomerate
From cannabis hype to beer-and-cannabis conglomerate: how Tilray is trying to turn a decade of dilution and volatility into a diversified, cash-generating platform built on craft beverages, medical distribution and North American optionality.
Canopy Growth Corporation ( $CGC )
Canada-based cannabis company with operations spanning adult-use and medical cannabis in Canada and international markets, medical brands (including expanding insured-patient channels) and inhalation hardware via premium vaporizer brand Storz & Bickel.
Strata Critical Medical Inc ( $SRTA ) Q4 2025 results and 2026 guidance
Time-critical logistics and clinical services for organ transplantation, now operating as a pure-play medical services platform after exiting passenger air mobility. Q4 2025 marks the first full quarter including Keystone’s perfusion business and a substantial reset of the 2026 growth trajectory.
uniQure N.V ( $QURE ) FDA says AMT-130 data not enough yet, shares collapse
uniQure’s stock is getting crushed after the company disclosed that the U.S. Food and Drug Administration does not consider current Phase I/II data for AMT-130 in Huntington’s disease sufficient to support a marketing application, and is instead recommending a fresh prospective, randomized, double-blind, sham surgery-controlled Phase III trial.
Outlook Therapeutics Inc ( $OTLK ) Updated march 6 post type A meeting with FDA
Outlook Therapeutics has become a fault line: some investors see a possible turnaround built on LYTENAVA’s European rollout and an FDA dialogue still technically open, others see only years of CRLs, value destruction and structural dilution risk. To really understand the stock you have to hold both sides of the story at the same time.
Intellia Therapeutics Inc ( $NTLA )
The FDA has lifted the clinical hold on MAGNITUDE, the Phase 3 trial of nexiguran ziclumeran (nex-z, ex NTLA-2001) in transthyretin cardiomyopathy. After months of uncertainty following a severe liver event and a patient death, Intellia and Regeneron can enrol again. This update revisits the thesis we outlined in the previous Merlintrader deep dive and asks what this decision really changes for the risk/reward profile of Intellia's in vivo CRISPR platform.
Lantheus ( $LNTH ) 2026: radiopharma at a crossroads with two March FDA decisions
March 6, 2026 – FDA PDUFA for new PSMA PET formulation (prostate cancer imaging) and March 29, 2026 – FDA PDUFA for OCTEVY, a new radiodiagnostic asset. These two decisions define the short-term binary risk / reward for LNTH after the Q4 2025 reset, while a third PDUFA for the tau tracer MK-6240 is scheduled for mid-August.